157 related articles for article (PubMed ID: 15576973)
1. [Selective estrogen receptor modulator].
Ohta H
Clin Calcium; 2004 Jan; 14(1):165-72. PubMed ID: 15576973
[TBL] [Abstract][Full Text] [Related]
2. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
Lee WL; Chao HT; Cheng MH; Wang PH
Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
[TBL] [Abstract][Full Text] [Related]
3. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
Shintani M
Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
[TBL] [Abstract][Full Text] [Related]
4. [Effects of SERMs on bone health. Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
Ohta H
Clin Calcium; 2010 Mar; 20(3):315-21. PubMed ID: 20190360
[TBL] [Abstract][Full Text] [Related]
5. [Raloxifene (Evista) in the treatment of postmenopausal osteoporosis--the profile of the patient].
Kastelan D; Korsić M
Reumatizam; 2005; 52(2):67-70. PubMed ID: 16689133
[TBL] [Abstract][Full Text] [Related]
6. [Evidence for the selective estrogen receptor modulator raloxifene--its pharmacological characteristics, efficacy and safety profiles].
Ohta H
Nihon Rinsho; 2009 May; 67(5):960-6. PubMed ID: 19432117
[TBL] [Abstract][Full Text] [Related]
7. [Selective estrogen receptor modulators (SERMs)].
Matsumoto T
Clin Calcium; 2006 Sep; 16(9):1520-25. PubMed ID: 16951478
[TBL] [Abstract][Full Text] [Related]
8. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
Ohta H
Clin Calcium; 2004 Oct; 14(10):73-80. PubMed ID: 15577135
[TBL] [Abstract][Full Text] [Related]
9. Raloxifene. Not better than estrogen.
Can Fam Physician; 2000 Aug; 46():1592-6, 1599-603. PubMed ID: 10955178
[TBL] [Abstract][Full Text] [Related]
10. [Effects of estrogen and selective estrogen receptor modulators on osteoporosis].
Urano T
Clin Calcium; 2005 Apr; 15(4):591-5. PubMed ID: 15802770
[TBL] [Abstract][Full Text] [Related]
11. [SERMs: an update for clinicians].
Ohta H
Clin Calcium; 2005 Apr; 15(4):637-42. PubMed ID: 15802777
[TBL] [Abstract][Full Text] [Related]
12. Prevention of breast cancer using selective oestrogen receptor modulators (SERMs).
Powles TJ
Breast Cancer Res; 2006; 8(5):111. PubMed ID: 17049068
[TBL] [Abstract][Full Text] [Related]
13. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
Sambrook P
Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
[TBL] [Abstract][Full Text] [Related]
14. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
Lewis JS; Jordan VC
Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
[TBL] [Abstract][Full Text] [Related]
15. Selective estrogen receptor modulators: A possible new treatment of osteoporosis in males.
Kastelan D; Giljevic Z; Kraljevic I; Korsic M
Med Hypotheses; 2006; 67(5):1052-3. PubMed ID: 16790322
[TBL] [Abstract][Full Text] [Related]
16. [Role of estrogen and selective estrogen receptor modulators in anti-aging].
Ohta H
Clin Calcium; 2008 Jul; 18(7):986-94. PubMed ID: 18591752
[TBL] [Abstract][Full Text] [Related]
17. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
Ohta H
Clin Calcium; 2008 Oct; 18(10):1442-50. PubMed ID: 18830041
[TBL] [Abstract][Full Text] [Related]
18. [Effects of SERMs on bone health. Efficacy of SERM for incidence of fractures in osteoporotic patients with lifestyle-related diseases].
Sakai A; Nakamura T
Clin Calcium; 2010 Mar; 20(3):322-9. PubMed ID: 20190361
[TBL] [Abstract][Full Text] [Related]
19. [SERMs for treatment of osteoporosis: state-of-the-art and perspectives].
Legrand E; Hoppé E; Chappard D; Audran M
Gynecol Obstet Fertil; 2006 May; 34(5):423-8. PubMed ID: 16697240
[TBL] [Abstract][Full Text] [Related]
20. [Raloxifene in postmenopausal women].
Trémollières F; Ribot C
Gynecol Obstet Fertil; 2006 Feb; 34(2):147-53. PubMed ID: 16483822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
